KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Minority Interest: 2009-2019

Historic Minority Interest for Ionis Pharmaceuticals (IONS) over the last 4 years, with Dec 2019 value amounting to $213.5 million.

  • Ionis Pharmaceuticals' Minority Interest rose 38.08% to $223.2 million in Q3 2020 from the same period last year, while for Sep 2020 it was $223.2 million, marking a year-over-year increase of 38.08%. This contributed to the annual value of $213.5 million for FY2019, which is 53.47% up from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Minority Interest of $213.5 million as of FY2019, which was up 53.47% from $139.1 million recorded in FY2018.
  • Ionis Pharmaceuticals' Minority Interest's 5-year high stood at $213.5 million during FY2019, with a 5-year trough of $84.3 million in FY2017.
  • For the 3-year period, Ionis Pharmaceuticals' Minority Interest averaged around $145.6 million, with its median value being $139.1 million (2018).
  • Data for Ionis Pharmaceuticals' Minority Interest shows a peak YoY skyrocketed of 65.05% (in 2018) over the last 5 years.
  • Over the past 3 years, Ionis Pharmaceuticals' Minority Interest (Yearly) stood at $84.3 million in 2017, then surged by 65.05% to $139.1 million in 2018, then surged by 53.47% to $213.5 million in 2019.